Dosing schedule for ZEN-3694

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Dosing schedule for ZEN-3694

in response to

Re: July 15, 2016

BearDownAZ

posted on Jul 13, 2016 05:10PM

Oops. I was a week off in one of my previous posts. June 15 was the start of dosing, and each cycle is 4 weeks, not 3 weeks as I stated previously. So today, July 13 marks the 4 week mark and they should be increasing to the next dose level any day now, barring any setbacks.

During Eric Campeau's NYAS presentation, he mentioned that once they find the maximum tolerated dose in the single agent trial (ZEN-3694 alone), they will start the combination therapy trial of ZEN-3694 and enzalutamide at the yet to be determined dose of ZEN-3694. This will most likely be in Q4 2016.